⚠ Evidence warning: Clinical trials or other evidence do not support the claim that more than 1 million women in the United States experience an episode of pelvic inflammatory disease each year. This page keeps it as a report of what people, websites or other media say.
Pelvic Inflammatory Disease
Table of Contents
Overview and Definition
Pelvic inflammatory disease (PID) is an infection of the female upper reproductive tract — the uterus (endometritis), fallopian tubes (salpingitis), ovaries (oophoritis), and the surrounding pelvic peritoneum. It occurs when bacteria, most often sexually transmitted, ascend from the vagina or cervix into structures that are normally sterile. PID is one of the most serious complications of sexually transmitted infections (STIs) and is a leading preventable cause of tubal-factor infertility, ectopic pregnancy, and chronic pelvic pain in reproductive-age women.
In a Centers for Disease Control and Prevention (CDC) analysis of the 2013–2014 national health survey (NHANES), 4.4% of sexually experienced U.S. women aged 18–44 reported ever having been diagnosed with PID; among women who reported a previous STI the figure was about 10% (10.0% in Black women and 10.3% in White women). The Centers for Disease Control and Prevention (CDC) estimates that more than 1 million women in the United States experience an episode of PID each year. The true incidence is higher because many cases are subclinical — producing no or minimal symptoms — yet still cause progressive tubal scarring. Prompt diagnosis and treatment are critical; each PID episode approximately doubles the risk of subsequent tubal factor infertility.
Causes and Risk Factors
PID is polymicrobial in most cases. The initial pathogens that disrupt the cervical mucus barrier are nearly always sexually transmitted:
- Neisseria gonorrhoeae — gram-negative diplococcus; causes a more acute, purulent PID with higher fever and greater tubal destruction than chlamydial PID.
- Chlamydia trachomatis — obligate intracellular bacterium; frequently produces subclinical or "silent" PID; responsible for the majority of chlamydial-attributable tubal infertility.
- Anaerobes and facultative bacteria — once the mucus barrier is breached, vaginal flora including Bacteroides, Prevotella, Gardnerella vaginalis, Streptococcus agalactiae, and gram-negative enteric organisms co-ascend and amplify tissue damage.
- Mycoplasma genitalium — an emerging cause increasingly linked to treatment-refractory PID; resistant to standard azithromycin regimens.
Risk Factors
- Age under 25 (highest risk group; cervical ectopy and less protective immune priming)
- Multiple or new sexual partners
- Prior PID episode
- Bacterial vaginosis (disrupts protective lactobacillus-dominant flora)
- Intrauterine device (IUD) insertion — risk window is the 21 days immediately after placement, not ongoing use
- Unprotected sexual intercourse
- Douching (disrupts vaginal pH and flora)
- Recent uterine instrumentation (endometrial biopsy, hysteroscopy, dilation and curettage)
Symptoms
Clinical presentation ranges from asymptomatic to life-threatening tubo-ovarian abscess (TOA). Classic findings include:
- Lower abdominal or pelvic pain — the most common symptom; typically bilateral, dull to crampy, often worsening during or after menses
- Abnormal vaginal discharge — mucopurulent or purulent; may be odorous
- Abnormal uterine bleeding — intermenstrual or post-coital spotting
- Dyspareunia — deep pelvic pain with intercourse
- Fever — temperature above 38.3°C (101°F) in more severe cases; often absent in mild or subclinical PID
- Nausea and vomiting — associated with more severe infection or peritoneal involvement
- Dysuria — urethral involvement or periurethral inflammation
- Right upper quadrant pain — raises suspicion for Fitz-Hugh-Curtis syndrome (perihepatitis; see below)
Diagnosis
The U.S. Centers for Disease Control and Prevention recommends a low threshold for empiric PID treatment because the consequences of untreated or delayed treatment (infertility, chronic pain, ectopic pregnancy) outweigh the risks of unnecessary antibiotics. Diagnosis is clinical.
U.S. Centers for Disease Control and Prevention Minimum Diagnostic Criteria (at least one present in a sexually active woman with no other explanation):
- Cervical motion tenderness (CMT) — pain when the cervix is moved laterally on bimanual exam; sometimes called "chandelier sign" in severe cases
- Uterine tenderness
- Adnexal tenderness
Additional Criteria Increasing Diagnostic Specificity:
- Oral temperature above 38.3°C (101°F)
- Mucopurulent cervical or vaginal discharge on speculum exam
- White blood cells on saline microscopy of vaginal secretions
- Elevated erythrocyte sedimentation rate (ESR) or C-reactive protein
- Laboratory confirmation of N. gonorrhoeae or C. trachomatis cervical infection
Imaging
- Transvaginal ultrasound (TVUS) — first-line imaging; identifies tubo-ovarian abscess (thickened, fluid-filled tubes; complex adnexal mass), free pelvic fluid
- Magnetic resonance imaging (MRI) — superior for soft-tissue characterization when TOA is suspected but ultrasound is equivocal
- Laparoscopy — definitive diagnostic standard (direct visualization of inflamed, erythematous fallopian tubes with purulent exudate); reserved for diagnostic uncertainty or treatment failure
Medical Treatment
The CDC guideline calls for treatment to start promptly once PID is suspected clinically. The goal is to cover the full spectrum of likely pathogens including gonorrhea, chlamydia, and anaerobes.
Outpatient Regimen (U.S. Centers for Disease Control and Prevention 2021 Guidelines — Preferred)
- Ceftriaxone 500 mg intramuscular (IM) single dose PLUS doxycycline 100 mg orally twice daily for 14 days WITH metronidazole 500 mg orally twice daily for 14 days
- Ceftriaxone provides gonorrhea coverage; doxycycline covers chlamydia; metronidazole extends anaerobic coverage and treats concurrent bacterial vaginosis (BV)
Why Metronidazole Was Added in 2021
The 2021 CDC guideline added metronidazole to the recommended PID regimen. The trial behind the change enrolled 233 women with acute PID, all treated with ceftriaxone and doxycycline, and gave half of them 14 days of metronidazole and half a dummy pill. Improvement at 3 days was the same in both groups. At 30 days, fewer women who took metronidazole still had anaerobic bacteria (bacteria that live without oxygen) in the lining of the womb (8% vs 21%), fewer had Mycoplasma genitalium in the cervix (4% vs 14%), and fewer still had pelvic tenderness (9% vs 20%). Side effects, and how well women kept taking their pills, were similar in both groups.
Alternative Outpatient Regimen
- Cefoxitin 2 g IM single dose plus probenecid 1 g orally, PLUS doxycycline 100 mg twice daily for 14 days WITH metronidazole 500 mg twice daily for 14 days
Inpatient (Intravenous) Regimen — Indications for Hospitalization
Hospitalization is recommended when: surgical emergency cannot be excluded; TOA is present; severe illness, nausea, vomiting, or high fever; outpatient treatment failed or cannot be tolerated; pregnancy.
- Cefoxitin 2 g intravenous (IV) every 6 hours PLUS doxycycline 100 mg orally or intravenous every 12 hours — after 24–48 hours of clinical improvement, the 2021 CDC regimen continues with oral doxycycline 100 mg twice daily PLUS metronidazole 500 mg orally twice daily to complete a 14-day total course
- Clindamycin 900 mg intravenous every 8 hours PLUS gentamicin loading dose intravenous or IM (2 mg/kg), then 1.5 mg/kg every 8 hours (or single daily dosing) — alternative for penicillin-allergic patients
Partner Treatment
The CDC guideline calls for all sexual partners from the preceding 60 days to be evaluated and treated empirically for gonorrhea and chlamydia regardless of test results. Expedited partner therapy (EPT) is legal and recommended in most US states when the partner cannot attend in person.
Mycoplasma genitalium
If M. genitalium is identified and the standard regimen fails, moxifloxacin 400 mg daily for 14 days is the preferred salvage therapy. Resistance-guided treatment is increasingly recommended where testing is available.
Surgical Treatment
- Tubo-ovarian abscess (TOA) drainage — most TOAs respond to intravenous antibiotics alone; those failing 48–72 hours of medical therapy are drained, typically via ultrasound-guided transvaginal or transabdominal aspiration. A 2024 review of 29 studies (2,890 women) found larger abscess size among the risk factors for antibiotics failing, alongside age, a history of intrauterine device use, being past menopause, diabetes, fever, high inflammation blood tests and earlier PID; the authors note that exactly which abscesses need surgery is not yet known
- Laparoscopic drainage or salpingectomy — indicated when drainage is not possible percutaneously, when the abscess has ruptured (surgical emergency), or when a unilateral TOA is removed in a woman who has completed childbearing
- Laparotomy — rarely needed; reserved for ruptured TOA with hemodynamic instability or when laparoscopic access is not feasible
Natural and Supportive Care
Supportive measures complement but do not replace antibiotic therapy. PID is a bacterial infection treated with systemic antibiotics, and a delay in treatment can result in permanent tubal damage.
- Rest — the usual guidance is pelvic rest (no intercourse) during and for 2 weeks after completing treatment; sexual activity before completing the full course risks re-exposure and treatment failure
- Pain management — nonsteroidal anti-inflammatory drugs (ibuprofen 400–600 mg every 6 hours with food) reduce inflammation and dysmenorrhea-type cramping; acetaminophen for patients with gastrointestinal (GI) intolerance
- Hydration and nutrition — fever and reduced intake increase dehydration risk; anti-inflammatory dietary patterns (Mediterranean-style, rich in omega-3 fatty acids) support immune recovery
- Probiotics — Lactobacillus rhamnosus and L. reuteri supplementation during and after antibiotic therapy may help restore vaginal and gut microbiome balance disrupted by broad-spectrum antibiotics; evidence is emerging rather than definitive
- Heat therapy — low-level heat pads reduce pelvic cramping and muscle spasm during recovery
- Douching — douching disrupts the protective vaginal flora that guards against ascending infection, and it is listed among the PID risk factors above
- Smoking — smoking impairs cervical immune defenses and increases STI susceptibility
- Barrier contraception — consistent condom use is the only proven behavioral intervention that reduces PID incidence by reducing STI transmission
- Doxycycline after sex — taking doxycycline within 72 hours after condomless sex (doxycycline post-exposure prophylaxis) has prevented STIs in men who have sex with men and in transgender women, but a 2023 trial in 449 Kenyan women aged 18–30 found no significant reduction: 25.1 vs 29.0 STIs per 100 person-years (relative risk 0.88, P = 0.51). Hair tests showed that many women assigned to doxycycline took it rarely, and every gonorrhea sample was resistant to doxycycline. It has therefore not been shown to prevent, in women, the infections that lead to PID
Complications
- Tubo-ovarian abscess (TOA) — occurs in 15–30% of hospitalized PID cases; can rupture causing life-threatening peritonitis and sepsis
- Ectopic pregnancy — tubal scarring from PID increases the risk of ectopic implantation 6–10-fold after a single episode; risk increases with each subsequent PID episode. In a Swedish cohort of women with laparoscopy-confirmed PID, 9.1% of first pregnancies afterwards were ectopic, against 1.4% in women with normal laparoscopy
- Tubal factor infertility — in the same Swedish cohort (1960–1984), 16.0% of women trying to conceive after PID did not, against 2.7% of controls, and 10.8% had confirmed tubal-factor infertility against none of the controls; the risk rose with the number and severity of PID episodes. An earlier Swedish series of 415 women found blocked tubes in 12.8% after one infection, 35.5% after two, and 75% after three or more
- Chronic pelvic pain — affects 20–30% of women after PID; caused by adhesions, hydrosalpinx, and central sensitization; can be debilitating
- Perihepatitis (Fitz-Hugh-Curtis syndrome) — perihepatic inflammation causing pleuritic right upper quadrant pain, sometimes mimicking cholecystitis or pleuritis
- Recurrent PID — 20–25% of women have a second episode, substantially increasing long-term complication risk
- Increased ovarian cancer risk — epidemiological data suggest a modest increased risk, possibly related to chronic inflammation
Fertility Impact
PID is the most common preventable cause of tubal-factor infertility in the developed world. The mechanism is inflammation-driven tubal damage: salpingitis triggers an exuberant repair response that deposits fibrin and collagen, causing peritubal adhesions, intraluminal synechiae, and loss of the ciliated epithelium that propels the oocyte toward the uterus.
- Hydrosalpinx — fluid-filled, distally obstructed fallopian tube; reduces in vitro fertilization (IVF) live-birth rates by approximately 50% when present; salpingectomy before IVF restores rates to baseline
- Subclinical PID — women who never received a PID diagnosis (because infection was mild) account for a substantial proportion of unexplained tubal infertility; chlamydia serology (immunoglobulin G (IgG) antibody to chlamydia heat-shock protein 60) is a surrogate marker
- IVF outcomes — tubal factor infertility is among the best IVF indications with live-birth rates approaching those of unexplained infertility when hydrosalpinx is surgically addressed
- Prevention — annual C. trachomatis and N. gonorrhoeae screening in sexually active women under 25 is the most evidence-based intervention to prevent PID-attributable infertility; the US Preventive Services Task Force (USPSTF) gives this a Grade B recommendation
Fitz-Hugh-Curtis Syndrome
Fitz-Hugh-Curtis syndrome is a rare complication of PID — specifically a perihepatitis — in which infection spreads from the pelvis along the right paracolic gutter to inflame the liver capsule (Glisson's capsule) and the adjacent anterior parietal peritoneum. It occurs in 4–14% of PID cases.
- Mechanism — most often associated with C. trachomatis; organisms or inflammatory mediators travel along the right paracolic gutter to the perihepatic space
- Symptoms — sharp, pleuritic right upper quadrant pain, often severe enough to dominate the clinical picture and overshadow pelvic symptoms; can mimic acute cholecystitis, right-sided pleuritis, or pulmonary embolism
- Diagnosis — clinical in the context of PID diagnosis; laparoscopy reveals the pathognomonic "violin string" adhesions between the anterior liver capsule and the parietal peritoneum
- Treatment — treated with the same antibiotic regimen as PID; adhesions rarely require surgical lysis unless causing chronic pain
- Prognosis — generally resolves with appropriate antibiotic therapy; chronic violin-string adhesions can cause persistent right upper quadrant pain in a minority of patients
Prognosis
Prognosis is strongly related to promptness of diagnosis and treatment. Women who receive antibiotics within the first 3 days of symptom onset have significantly lower rates of infertility and chronic pelvic pain compared to those treated later. Key prognostic points:
- Single episode of mild-to-moderate PID treated promptly — most women recover fully without long-term sequelae
- TOA — responds to intravenous antibiotics in 75–90% of cases, less often when the abscess is larger; surgical drainage is needed in 15–30%
- Recurrent PID — each episode multiplicatively increases infertility risk; STI screening, partner treatment, and safer sex are the measures that prevent recurrence
- Subclinical PID — because it goes untreated, it may cause the same or greater tubal damage as symptomatic PID before being discovered during infertility workup
Key Research Papers
- Workowski KA, Bachmann LH, Chan PA, et al. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recomm Rep. 2021;70(4):1–187. — PubMed PMID: 34292926 · doi:10.15585/mmwr.rr7004a1
- Wiesenfeld HC, Hillier SL, Meyn LA, Amortegui AJ, Sweet RL. Subclinical Pelvic Inflammatory Disease and Infertility. Obstetrics & Gynecology. 2012;120(1):37–43. — PubMed PMID: 22678036 · doi:10.1097/aog.0b013e31825a6bc9
- Westrom L, Joesoef R, Reynolds G, Hagdu A, Thompson SE. Pelvic Inflammatory Disease and Fertility: A Cohort Study of 1,844 Women with Laparoscopically Verified Disease and 657 Control Women with Normal Laparoscopic Results. Sexually Transmitted Diseases. 1992;19(4):185–192. — PubMed PMID: 1411832 · doi:10.1097/00007435-199207000-00001
- Haggerty CL, Hillier SL, Bass DC, Ness RB; PID Evaluation and Clinical Health (PEACH) Study Investigators. Bacterial Vaginosis and Anaerobic Bacteria Are Associated with Endometritis. Clinical Infectious Diseases. 2004;39(7):990–995. — PubMed PMID: 15472851 · doi:10.1086/423963
- Ness RB, Soper DE, Holley RL, et al. Effectiveness of Inpatient and Outpatient Treatment Strategies for Women with Pelvic Inflammatory Disease: Results from the Pelvic Inflammatory Disease Evaluation and Clinical Health (PEACH) Randomized Trial. American Journal of Obstetrics & Gynecology. 2002;186(5):929–937. — PubMed PMID: 12015517 · doi:10.1067/mob.2002.121625
- Hoenderboom BM, van Benthem BHB, van Bergen JEAM, et al. Relation Between Chlamydia trachomatis Infection and Pelvic Inflammatory Disease, Ectopic Pregnancy and Tubal Factor Infertility in a Dutch Cohort of Women Previously Tested for Chlamydia in a Chlamydia Screening Trial. Sexually Transmitted Infections. 2019;95(4):300–306. — PubMed PMID: 30606817 · doi:10.1136/sextrans-2018-053778
- Stacey CM, Munday PE, Taylor-Robinson D, Thomas BJ, Gilchrist C, Ruck F, Ison CA, Beard RW. A Longitudinal Study of Pelvic Inflammatory Disease. British Journal of Obstetrics and Gynaecology. 1992;99(12):994–999. — PubMed PMID: 1477024 · doi:10.1111/j.1471-0528.1992.tb13705.x
- Paavonen J, Westrom L, Eschenbach D. Pelvic Inflammatory Disease. In: Holmes KK, Sparling PF, Mardh PA, et al, eds. Sexually Transmitted Diseases. 4th ed. McGraw-Hill; 2008.
- Brunham RC, Gottlieb SL, Paavonen J. Pelvic Inflammatory Disease. New England Journal of Medicine. 2015;372(21):2039–2048. — PubMed PMID: 25992748 · doi:10.1056/NEJMra1411426
- Curry A, Williams T, Penny ML. Pelvic Inflammatory Disease: Diagnosis, Management, and Prevention. American Family Physician. 2019;100(6):357–364. — PubMed PMID: 31524362
- Scholes D, Stergachis A, Heidrich FE, Andrilla H, Holmes KK, Stamm WE. Prevention of Pelvic Inflammatory Disease by Screening for Cervical Chlamydial Infection. New England Journal of Medicine. 1996;334(21):1362–1366. — PubMed PMID: 8614421 · doi:10.1056/nejm199605233342103
- Kreisel K, Torrone E, Bernstein K, Hong J, Gorwitz R. Prevalence of Pelvic Inflammatory Disease in Sexually Experienced Women of Reproductive Age — United States, 2013–2014. MMWR Morb Mortal Wkly Rep. 2017;66(3):80–83. — PubMed PMID: 28125569 · doi:10.15585/mmwr.mm6603a3
- Wiesenfeld HC, Meyn LA, Darville T, Macio IS, Hillier SL. A Randomized Controlled Trial of Ceftriaxone and Doxycycline, With or Without Metronidazole, for the Treatment of Acute Pelvic Inflammatory Disease. Clinical Infectious Diseases. 2021;72(7):1181–1189. — PubMed PMID: 32052831 · doi:10.1093/cid/ciaa101
- Stewart J, Oware K, Donnell D, et al; dPEP Kenya Study Team. Doxycycline Prophylaxis to Prevent Sexually Transmitted Infections in Women. New England Journal of Medicine. 2023;389(25):2331–2340. — PubMed PMID: 38118022 · doi:10.1056/NEJMoa2304007
- Weström L. Effect of Acute Pelvic Inflammatory Disease on Fertility. American Journal of Obstetrics & Gynecology. 1975;121(5):707–713. — PubMed PMID: 123123 · doi:10.1016/0002-9378(75)90477-9
- Kinay T, Akay A, Aksoy M, Celik Balkan F, Engin Ustun Y. Risk Factors for Antibiotic Therapy Failure in Women with Tubo-Ovarian Abscess: A Systematic Review and Meta-Analysis. Journal of Obstetrics and Gynaecology Research. 2024;50(3):298–312. — PubMed PMID: 38184888 · doi:10.1111/jog.15870